breast cancer
Conditions
Interventions
neoadjuvant endocrine therapy (tamoxifen for premenopausal patients or letrozole for postmenopausal patients)
Sponsors
Keio University School of Medicine
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Histologically confirmed invasive ductal carcinoma 2. Estrogen receptor and/or progesterone receptor positive 3. No previous treatment for the breast cancer 4. Subjects must meet all of the following criteria for inclusion in the study. 1) AST/ALT: <2 times the upper limit of the normal range 2) Serum creatinine: <1.5 times the upper limit of the normal range 5. ECOG PS of 0-2. 6. Patients from written informed consent to participation in the study has been obtained
Exclusion criteria
Exclusion criteria: 1. During pregnancy or lactation 2. With active other cancer 3. History of drug allergy 4. Significant illness that might influence the tolerability of treatment (interstitual pneumonia or lung fibrosis, myocardial infarction or congestive heart failure at the past history, or patients who need treatment of ischemic heart disease, arryhythmia or vascular disorder) 5. Severe myelosuppression 6. Severe kidney failure or liver failure 7. Active infectious disease 8. Inflammatory or bilateral breast cancer 9. Patients whom doctors judged inadequate to the enrollment of this study by other reasons
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| disease free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical usefulness | — |
Countries
Japan
Contacts
Public ContactHiromitsu Jinno
Keio University School of Medicine Department of Surgery
Outcome results
None listed